Literature DB >> 10411305

The shed thyrotropin receptor is primarily a carboxyl terminal truncated form of the A subunit, not the entire A subunit.

K Tanaka1, G D Chazenbalk, S M McLachlan, B Rapoport.   

Abstract

The TSH receptor (TSHR) sheds its A subunit, particularly when cells are cultured in serum-poor medium. This shed A subunit is reported to be smaller than the cell-associated receptor because of the loss of glycan without change in its polypeptide core. Contrary to previous deductions, we now find that the 'small' shed A subunit has lost a glycan moiety because of the proteolytic clipping of a small C-terminal fragment containing an Asn-linked glycan. Moreover, this lost peptide fragment contains cysteine residues likely involved in A subunit linkage to the membrane-associated B subunit. Progressive lowering of the serum concentration in culture medium accentuates the process. Therefore, 'small' A subunit shedding does not appear related to a physiological mechanism involving disulfide bond reduction. On the other hand, we detected, for the first time, shedding of a lesser amount of normal-sized, in addition to small, A subunits, especially by cells cultured in standard serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411305     DOI: 10.1016/s0303-7207(99)00018-0

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

Review 1.  Review and hypothesis: does Graves' disease develop in non-human great apes?

Authors:  Sandra M McLachlan; Kristine Alpi; Basil Rapoport
Journal:  Thyroid       Date:  2011-11-08       Impact factor: 6.568

2.  Allosteric modulators hit the TSH receptor.

Authors:  Terry F Davies; M Rejwan Ali; Rauf Latif
Journal:  Endocrinology       Date:  2014-01       Impact factor: 4.736

3.  A unique mouse strain that develops spontaneous, iodine-accelerated, pathogenic antibodies to the human thyrotrophin receptor.

Authors:  Basil Rapoport; Holly A Aliesky; Bianca Banuelos; Chun-Rong Chen; Sandra M McLachlan
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

4.  A Mouse Thyrotropin Receptor A-Subunit Transgene Expressed in Thyroiditis-Prone Mice May Provide Insight into Why Graves' Disease Only Occurs in Humans.

Authors:  Sandra M McLachlan; Holly A Aliesky; Basil Rapoport
Journal:  Thyroid       Date:  2019-07-03       Impact factor: 6.568

Review 5.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

6.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

7.  A monoclonal antibody with thyrotropin (TSH) receptor inverse agonist and TSH antagonist activities binds to the receptor hinge region as well as to the leucine-rich domain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2009-03-19       Impact factor: 4.736

Review 8.  TSH Receptor Cleavage Into Subunits and Shedding of the A-Subunit; A Molecular and Clinical Perspective.

Authors:  Basil Rapoport; Sandra M McLachlan
Journal:  Endocr Rev       Date:  2016-02       Impact factor: 19.871

9.  The thyrotropin receptor hinge region as a surrogate ligand: identification of loci contributing to the coupling of thyrotropin binding and receptor activation.

Authors:  Chun-Rong Chen; Larry M Salazar; Sandra M McLachlan; Basil Rapoport
Journal:  Endocrinology       Date:  2012-10       Impact factor: 4.736

Review 10.  TSH Receptor Cleavage Into Subunits and Shedding of the A-Subunit; A Molecular and Clinical Perspective.

Authors:  Basil Rapoport; Sandra M McLachlan
Journal:  Endocr Rev       Date:  2016-01-22       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.